# xForest Therapeutics Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/xforest-therapeutics-co

- Industry: Pharmaceuticals
- Headquarters: Kyoto-shi, Japan
- Website: www.xforestx.com/
- Total disclosed funding: $1.3M
- Latest round: Series A (Jan 24, 2025)
- Investors on record: 3

## About

Based in Japan, xForest Therapeutics Co., Ltd. focuses on innovative drug discovery. The company specializes in developing small molecule therapeutics aimed at disease-specific RNA targets, utilizing advanced technology platforms.xForest Therapeutics Co., Ltd. was founded in 2020 and is headquartered in Kyoto-shi, Japan. The company operates independently and has not undergone any notable pivots or mergers. Kaoru Komatsu, the founder, has established a strong background in drug development. As of January 2025, xForest has successfully completed a SEED funding round, raising JPY 133.277 mn, with a total amount raised of JPY 133.277 mn and a current company valuation of JPY 3,794.008 mn. The most recent deal dates back to January 24, 2025.xForest Therapeutics specializes in innovative drug discovery through its proprietary technology platform known as "FOREST," which focuses on RNA structures as therapeutic targets. This platform integrates advanced biochemical analysis systems that evaluate approximately 1,000 species of RNA, alongside sophisticated in silico analysis pipelines. The main goal of these technologies is to identify highly specific RNA-binders, which facilitate the discovery of RNA-targeting drugs. The company primarily targets pharmaceutical companies and academic institutions across North America, Europe, and Asia, delivering efficient solutions in drug discovery.xForest Therapeutics generates revenue primarily through strategic collaborations with pharmaceutical companies, involving milestone payments based on specific research and development targets and potential royalties from future product sales. The company also benefits from grant funding, including recent awards from the New Energy and Industrial Technology Development Organization (NEDO). Transactions typically occur on a B2B basis, where xForest provides its proprietary technology and expertise for exploring multiple therapeutic targets, enhancing treatment accessibility for rare diseases.In January 2025, xForest Therapeutics Co., Ltd. raised an undisclosed amount in SEED funding from new investors Miyako Capital and KSP, with returning investor ANRI also participating. This round was part of a larger JPY 1.95 billion in SEED funding and grant funding. The recent funding will be utilized to accelerate the development of its lead compound creation platform for drug development. The company aims to expand its market reach further into North America, Europe, and Asia by enhancing its product offerings and entering new geographic regions.

## Funding rounds

- Series A, Jan 24, 2025 — Miyako Capital, ANRI, KSP
- Seed, Oct 6, 2020, $1.3M — ANRI

## Investors

- ANRI (https://capitalatlas.ai/funds/anri) — Seed, Series A
- Miyako Capital (https://capitalatlas.ai/funds/miyako-capital) — Series A
- KSP (https://capitalatlas.ai/funds/ksp) — Series A